biostudies-literatureUnknown13(23)Lee CJClear cell sarcoma (CCSA) is characterized by a chromosomal translocation leading to <i>EWSR1</i> rearrangement, resulting in aberrant transcription of multiple genes, including <i>MET</i>. The EORTC 90101 phase II trial evaluated the MET inhibitor crizotinib in CCSA but resulted in only sporadic responses. We performed an in-depth histopathological and molecular analysis of archival CCSA samples to identify alterations potentially relevant for the treatment outcome. Immunohistochemical characterization of MET signaling was performed using a tissue microarray constructed from 32 CCSA cases. The DNA from 24 available tumor specimens was analyzed by low-coverage whole-genome sequencing and whole-exome sequencing for the detection of recurrent copy number alterations (CNAs) and mutations. A pCancers6057https://www.ebi.ac.uk/biostudies/studies/S-EPMC8657105biostudies-literatureHistopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial.PMC8657105Sciot RRutkowski PLambrechts DModave EStacchiotti SLee CJSchoffski PBlay JYBoeckx BDebiec-Rychter MWozniak AfalseHistopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial.Clear cell sarcoma (CCSA) is characterized by a chromosomal translocation leading to <i>EWSR1</i> rearrangement, resulting in aberrant transcription of multiple genes, including <i>MET</i>. The EORTC 90101 phase II trial evaluated the MET inhibitor crizotinib in CCSA but resulted in only sporadic responses. We performed an in-depth histopathological and molecular analysis of archival CCSA samples to identify alterations potentially relevant for the treatment outcome. Immunohistochemical characterization of MET signaling was performed using a tissue microarray constructed from 32 CCSA cases. The DNA from 24 available tumor specimens was analyzed by low-coverage whole-genome sequencing and whole-exome sequencing for the detection of recurrent copy number alterations (CNAs) and mutations. A p2021-01-01T00:00:00Z2021 Dec2026-06-19T03:21:32.095Z2022-02-11T15:22:16.509ZS-EPMC86571053488516510.3390/cancers13236057